Reproductive system

Dr. John Mulhall Joins FirmTech's Scientific Advisory Board to Promote Innovation in Men's Sexual Health

Retrieved on: 
Wednesday, March 6, 2024
Master of Science, FACS, Private practice, Woman, Multimedia, Research, Performance, MD, Vital signs, Pleasure, Erectile dysfunction, Health, Male, FRCSI, Reproductive system, Happiness, Journal, FACEP, Cancer, Birth control

BOZEMAN, Mont., March 6, 2024 /PRNewswire/ -- FirmTech, the revolutionary sexual technology wellness company, today announced that John P. Mulhall, MD, MSc, FECSM, FACS, FRCSI, has joined its Scientific Advisory Board. Dr. Mulhall brings decades of experience and leadership in men's sexual health care to FirmTech, and a personal commitment to drive innovation that will improve men's lives. He will partner with renowned colleagues to provide independent guidance, analysis of sextech data, and evaluation of FirmTech product offerings to ensure they are science-backed and effective for men and women who want to improve their sexual performance and health.

Key Points: 
  • A world-renowned leader in men's sexual health, Mulhall joins esteemed colleagues dedicated to providing science-backed research that advances the field of sexual wellness
    BOZEMAN, Mont., March 6, 2024 /PRNewswire/ -- FirmTech , the revolutionary sexual technology wellness company, today announced that John P. Mulhall, MD, MSc, FECSM, FACS, FRCSI, has joined its Scientific Advisory Board.
  • Dr. Mulhall brings decades of experience and leadership in men's sexual health care to FirmTech, and a personal commitment to drive innovation that will improve men's lives.
  • "Wearable technology is the wave of the future for sexual wellness, and I'm excited to join FirmTech's independent scientific advisory board to help drive science-backed innovation," said Dr. Mulhall.
  • Dr. Mulhall is the Director of the Male Sexual and Reproductive Medicine Program at Memorial Sloan Kettering Cancer Center in New York City.

Estée Lauder Announces New Skin Longevity Initiative, The Next Frontier of Beauty

Retrieved on: 
Thursday, December 14, 2023
Research, Luxury, Women, Specialty, Health Technology, Consumer, Health, Cosmetics, Retail, Science, Diamond, Life expectancy, Editorial, Norm (mathematics), Aesthetics, Senior, Assistant professor, Reproductive system, Creative, Congress, Human, Movement, Life, Ageing, Style Design College, Ultimate Diamond, Public policy, Weill Cornell Medicine, Beauty, University of California, Berkeley, Skin, University, Global Brands Group, Sirtuin, Murphy, Toxicology, Stanford University, International Chinese Language Program, Biology, Pharmaceutical industry, Management, Psychology, List of life sciences, Dermatology, Medicine, Longevity

Estée Lauder today announces its new Skin Longevity platform, grounded in 15-years of expertise in pioneering skin longevity research.

Key Points: 
  • Estée Lauder today announces its new Skin Longevity platform, grounded in 15-years of expertise in pioneering skin longevity research.
  • Estée Lauder also announces its support of the Stanford Center on Longevity and its new Program on Aesthetics & Culture, whose work will include research assessing perceptions on longevity and vitality.
  • “The Estée Lauder brand has always been at the forefront of breakthrough skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
  • Building on the brand’s commitment to furthering longevity research, Estée Lauder announces its support of the Stanford Center on Longevity, a cross-disciplinary research center at Stanford University.

Innovation Fertility and Sunfish Launch a Groundbreaking Program to Reduce the Financial Stress of In Vitro Fertilization for Aspiring Parents

Retrieved on: 
Tuesday, September 12, 2023
Insurance, Uncertainty, Fintech, Partnership, Pregnancy, Society, Billings Clinic, Anxiety, Parent, St. Louis Fed Financial Stress Index, Multimedia, Reproductive endocrinology and infertility, IVF, Fertility, Assisted reproductive technology, Patient, Reproductive system, Family, Data science, Birth control, Sunfish

The two are jointly launching Sunfish's new Gold Membership Program, which uses proprietary analytics to develop custom financial plans to cover in vitro fertilization (IVF) treatments for individual patients.

Key Points: 
  • The two are jointly launching Sunfish's new Gold Membership Program, which uses proprietary analytics to develop custom financial plans to cover in vitro fertilization (IVF) treatments for individual patients.
  • Innovation Fertility is launching this new program for patients at several clinics nationwide, including RMA Michigan, Reproductive Specialists of the Carolinas, and Billings Clinic.
  • The Sunfish Gold Membership Program will help reduce patients' financial burden and uncertainty while seeking fertility care, which is revolutionary in the fertility industry," states Dwight Ryan, CEO of Innovation Fertility.
  • Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals with the support of some of the premier reproductive endocrinologists.

In Celebration of "Orgasm Day" The Cellular Medicine Association Offers a Free Course, The Female Orgasm System

Retrieved on: 
Thursday, July 27, 2023
Food, CMA, Life, Female reproductive system, Education, Anxiety, Physician, Respiratory disease, Circulatory System (band), Circulatory system, Orgasm, Respiratory system of insects, Respiratory system, Woman, Medicine, DSM-IV codes, Systems analysis, Platelet-rich plasma, Trachea, Blood, Reproductive system, Testosterone and the cardiovascular system, CQD, Anorgasmia, Child, Anemia, Engineering, Aesthetics, Pleasure, Periodic breathing, Diagnosis, Erectile dysfunction, Research, Book, Music, Female, Urinary incontinence, Nursing, Publishing, Medical device, MD

Music and food are sometimes called "orgasmic" because orgasm is considered to be the ultimate pleasure; but orgasm is not just about pleasure.

Key Points: 
  • Music and food are sometimes called "orgasmic" because orgasm is considered to be the ultimate pleasure; but orgasm is not just about pleasure.
  • Similarly, the Reproductive System and the Orgasm System share components but are not the same."
  • Dr. Runels, the inventor of the O-Shot® procedure , author of multiple research papers and books, and first to use the terminology "Female Orgasm System," is offering an online seven-week course teaching the Female Orgasm System in hopes of narrowing the orgasm gap.
  • The course is sponsored by the Cellular Medicine Association (CMA) .

Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive

Retrieved on: 
Thursday, July 13, 2023
Pregnancy, Society, Pill, Obstetrics, American College of Obstetricians and Gynecologists, PRGO, Birth, NDAC, Health, Women's health, Woman, American Academy, Adolescence, Perrigo, American Medical Association, Family medicine, Adolescent health, OTC, Norgestrel, American Academy of Family Physicians, Consumer, Reproductive system, American College, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Gynaecology, NYSE, Food, Medicine, Birth control

DUBLIN, July 13, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration (FDA) approved Opill®, a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages.

Key Points: 
  • DUBLIN, July 13, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration (FDA) approved Opill®, a progestin-only daily oral contraceptive, for over-the-counter (OTC) use for all ages.
  • "Today marks a truly momentous day for women's health nationwide," said Perrigo President and Chief Executive Officer Patrick Lockwood-Taylor.
  • "Today's approval is a groundbreaking expansion for women's health in the U.S., and a significant milestone towards addressing a key unmet need for contraceptive access," said Frederique Welgryn, Perrigo Global Vice President for Women's Health.
  • "Perrigo is committed to making Opill®, which is now the most effective method available OTC at preventing pregnancy(1), accessible and affordable to women and people of all ages.

Inteleos Announces Compañeros En Salud- Partners in Health as MissionPOCUS Selection for 2023

Retrieved on: 
Wednesday, June 7, 2023
PIH, CES, Partner, POCUS, Physician, Nursing, Reproductive system, Pediatrics, Health

ROCKVILLE, Md., June 07, 2023 (GLOBE NEWSWIRE) -- Today the Inteleos Foundation and the POCUS Certification Academy under Inteleos announced Compañeros En Salud (CES) a sister organization of Partners in Health (PIH) as the selection for their MissionPOCUS™ collaboration for 2023.

Key Points: 
  • ROCKVILLE, Md., June 07, 2023 (GLOBE NEWSWIRE) -- Today the Inteleos Foundation and the POCUS Certification Academy under Inteleos announced Compañeros En Salud (CES) a sister organization of Partners in Health (PIH) as the selection for their MissionPOCUS™ collaboration for 2023.
  • Through this grant, Compañeros En Salud will conduct monthly trainings over the period of six months with a team of physicians, nurses, midwives, pediatricians, and medical interns, across the Primary Care and Sexual and Reproductive Health programs.
  • Dr. Bruno Raul Vargas García, a clinical supervisor at Compañeros En Salud, shares that, “This grant is giving us the opportunity to build capacity and train the next generation of POCUS users with a focus on health equity.”
    The Inteleos Foundation is proud to sponsor the 2023 MissionPOCUS award.
  • For more information about MissionPOCUS or the 2023 pilot program, visit www.pocus.org/MissionPOCUS

Reproductive Specialists of the Carolinas Welcomes Accomplished Fertility Doctor And Innovator To Practice

Retrieved on: 
Wednesday, June 7, 2023
Yoga, REI, Reproductive medicine, Artificial insemination, Travel, University, American Board of Obstetrics and Gynecology, Education, Friends, Atrium Health, Clinical and Translational Science Award, ART, DRS, Infertility, RSC, Washington University in St. Louis, IVF, IUI, American Board of Commissioners for Foreign Missions, MSCI, Dream, Medical director, Patient, ICTS, Fertility, Furman University, University of Louisville School of Medicine, Gynaecology, Reproductive system, NC, Health, Family, Pacific coast, Medical device, Birth control, Science, Obstetrics

CHARLOTTE, N.C., June 7, 2023 /PRNewswire-PRWeb/ -- Reproductive Specialists of the Carolinas (RSC), a leading fertility practice, is proud to announce that Dr. Ashley Eskew, an award-winning, renowned reproductive endocrinologist and infertility specialist, recently joined this boutique fertility practice as their third doctor. She complements her diverse medical experience with a unique clinical background. Dr. Eskew continues to provide RSC patients with a high level of advanced and inclusive reproductive care.

Key Points: 
  • CHARLOTTE, N.C., June 7, 2023 /PRNewswire-PRWeb/ -- Reproductive Specialists of the Carolinas (RSC), a leading fertility practice, is proud to announce that Dr. Ashley Eskew, an award-winning, renowned reproductive endocrinologist and infertility specialist, recently joined this boutique fertility practice as their third doctor.
  • "Becoming a part of an innovative practice like Reproductive Specialists of the Carolinas, and working alongside Drs.
  • Reproductive Specialists of the Carolinas is located at 1918 Randolph Rd, Ste 410, Charlotte, NC 28207-1109.
  • Dr. Matrika Johnson, Reproductive Specialists of the Carolinas, 1 704-247-2209, [email protected]

PINNEY ASSOCIATES, INC., ANNOUNCES PROMOTIONS OF KEY MEMBERS TO LEADERSHIP TEAM

Retrieved on: 
Tuesday, May 16, 2023
Central nervous system, Rx, Health policy, Obstetrics, Senior, Public, Policy, Business, Cannabinoid, Tobacco, CNS, Sale, Food and Drug Administration, Joint meetings of the Australian Parliament, MD, Perrigo, OTC, Reproductive system, FDA, Death, Smoking, Food, Disease, Pharmaceutical industry, Mobile phone

Lucy Owen, in her 25 years at Pinney Associates, has made significant contributions to public health by guiding clients through the complex and dynamic Rx-to-OTC switch regulatory process.

Key Points: 
  • Lucy Owen, in her 25 years at Pinney Associates, has made significant contributions to public health by guiding clients through the complex and dynamic Rx-to-OTC switch regulatory process.
  • Robyn Gougelet, who has been with the firm for eight years, has been a key member of our tobacco harm reduction team.
  • "We are thrilled to have promoted these talented individuals to our leadership team," said John Pinney, Founder and Chair of Pinney Associates.
  • Pinney Associates' experts have extensive expertise and experience in medicines with abuse potential, Rx-to-OTC switch and consumer healthcare products.

FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use

Retrieved on: 
Wednesday, May 10, 2023
Pregnancy, Use, Obstetrics, American College of Obstetricians and Gynecologists, LCS, PRGO, Public, Physician, Birth, NDAC, Health, Women's health, Woman, American Academy, Perrigo, ACCESS, American Medical Association, Family medicine, OTC, Norgestrel, American Academy of Family Physicians, Consumer, Reproductive system, American College, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Gynaecology, NYSE, Food, Pharmaceutical industry, Birth control

The joint committee's vote, while not binding, will be considered by the FDA when making its final decision regarding the potential approval of Opill® for OTC use, which is expected later this year.

Key Points: 
  • The joint committee's vote, while not binding, will be considered by the FDA when making its final decision regarding the potential approval of Opill® for OTC use, which is expected later this year.
  • "Today's vote to recommend a switch of Opill® to OTC is a new, groundbreaking chapter in reproductive health.
  • "We are motivated by the millions of people who need easy access to safe and effective contraception.
  • Notably, adherence in the ACCESS study, taking the pill daily, was no different from published data on oral contraception adherence in the prescription setting(1).

Covis Pharma Responds to Presiding Officer’s Report Summarizing FDA Advisory Committee Hearing

Retrieved on: 
Tuesday, March 7, 2023
Reproductive system, Doctor of Philosophy, Commissioner of Food and Drugs, Pregnancy, FDA, Center for Drug Evaluation and Research, Safety, CDER, Woman, Preterm birth, Patient, Obstetrics, COVI-VAC (U.S. COVID-19 vaccine), Risk, Hearing, Pharmaceutical industry

ZUG, Switzerland, March 07, 2023 (GLOBE NEWSWIRE) -- Covis Pharma Group (“Covis”), today announced it has submitted a response to the Presiding Officer’s report summarizing the October 17-19, 2022 public hearing and providing recommendations on the Center for Drug Evaluation and Research’s (CDER) proposal to withdrawal approval for Makena® (hydroxyprogesterone caproate injection), the only FDA-approved treatment to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth.

Key Points: 
  • Covis appreciates the opportunity it was afforded to present its view that relevant safety and efficacy data continue to support the approval of Makena, at least in a narrower indication.
  • Nevertheless, Covis respects the recommendations of the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee, and, in light of its recommendations, is seeking to voluntarily withdraw the Makena NDA.
  • Shortly after the hearing, Covis outlined a plan for voluntary withdrawal that would have obviated the need for further proceedings.
  • As the company awaits a final decision by the FDA, Makena remains approved and the product label is unchanged at this time.